Acute hypersensitivity reactions to chemotherapy agents: An overview

Inflammation and Allergy - Drug Targets

Volumn 9, Issue 3, 2010, Pages 206-213

  Syrigou, Ekaterini ^a   Triantafyllou, Olga ^a   Makrilia, Nektaria ^a   Kaklamanos, Ioannis ^a   Kotanidou, Anastasia ^a   Manolopoulos, Leonidas ^a   Syrigos, Kostas ^a  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

Author keywords

Antineoplastic drugs; Chemotherapy agents; Desensitization; Hypersensitivity reactions; Platinum containing compounds; Skin tests; Treatment

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ASPARAGINASE; CARBOPLATIN; CIMETIDINE; CISPLATIN; CORTICOSTEROID; DAUNORUBICIN; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; DOXORUBICIN; EPIPODOPHYLLOTOXIN; EPIRUBICIN; ETOPOSIDE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; IDARUBICIN; OXALIPLATIN; PACLITAXEL; RANITIDINE; TENIPOSIDE;

ABDOMINAL PAIN; ANGIONEUROTIC EDEMA; ANXIETY; ARTICLE; BACKACHE; BRADYCARDIA; BRONCHOSPASM; CHEST TIGHTNESS; DESENSITIZATION; DRUG HYPERSENSITIVITY; DRUG RECHALLENGE; DYSPNEA; ERYTHEMA; FLUSHING; HUMAN; HYPERTENSION; HYPOTENSION; INCIDENCE; NAUSEA; PATHOGENESIS; PREMEDICATION; SKIN TEST; TACHYCARDIA; THORAX PAIN; URTICARIA; WHEEZING;

EID: 77958499254     PISSN: 18715281     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152810792231887     Document Type: Article

References (92)

1. Zanotti, K.M.; Markman, M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf., 2001, 24(10), 767-779.
2. Jutel, M.; Akdis, M.; Akdis, C.A. Histamine, histamine receptors and their role in immune pathology. Clin. Exp. Allergy, 2009, 39(12), 1786-1800.
3. Hausmann, O.; Schnyder, B.; Pichler, W.J. Drug hypersensitivity reactions involving skin. Handb. Exp. Pharmacol., 2010, (196), 29-55.
4. Shepherd, G.M. Hypersensitivity reactions to chemotherapeutic drugs. Clin. Rev. Allergy Immunol., 2003, 24(3), 253-262.
5. Katirtzoglou, N.; Gkiozos, I.; Makrilia, N.; Tsaroucha, E.; Rapti, A.; Stratakos, G.; Fountzilas, G.; Syrigos, K.N. Carboplatin plus pemetrexed as first-line treatment of patients with malignant pleural mesothelioma: a phase II study. Clin. Lung Cancer, 2010, 11(1), 30-35.
6. Karapanagiotou, E.M.; Boura, P.G.; Papamichalis, G.; Konstantinou, M.; Sepsas, E.; Chamalakis, G.; Simsiris, P.; Gkiozos, I.; Syrigos, K.N. Carboplatin-pemetrexed adjuvant chemotherapy in resected non-small cell lung cancer (NSCLC): a phase II study. Anticancer Res., 2009, 29(10), 4297-4301.
7. Kosmidis, P.A.; Dimopoulos, M.A.; Syrigos, K.; Nicolaides, C.; Aravantinos, G.; Boukovinas, I.; Pectasides, D.; Fountzilas, G.; Bafaloukos, D.; Bacoyiannis, C.; Kalofonos, H.P. Gemcitabine versus gemcitabine-carboplatin for patients with advanced nonsmall cell lung cancer and a performance status of 2: a prospective randomized phase II study of the Hellenic Cooperative Oncology Group. J. Thorac. Oncol., 2007, 2(2), 135-140.
8. Polyzos, A.; Syrigos, K.; Stergiou, J.; Panopoulos, C.; Potamianou, A.; Vamvakas, L.; Georgoulias, V. Phase I trial of weekly docetaxel with a 4-weekly cisplatin administration in patients with advanced gastric carcinoma. Cancer Chemother. Pharmacol., 2005, 55(5), 466-470.
9. Bamias, A.; Syrigos, K.; Fountzilas, G.; Tzamakou, E.; Soulti, K.; Karavasilis, V.; Alamanos, Y.; Christodoulou, C.; Pavlidis, N. Intensified bimonthly cisplatin with bolus 5-fluorouracil, continuous 5-fluorouracil and high-dose leucovorin (LV5FU2) in Patients with advanced gastrointestinal carcinomas: a phase I dosefinding and pharmacokinetic study. Am. J. Clin. Oncol., 2004, 27(5), 465-471.
10. Georgoulias, V.; Agelidou, A.; Syrigos, K.; Rapti, A.; Agelidou, M.; Nikolakopoulos, J.; Polyzos, A.; Athanasiadis, A.; Tselepatiotis, E.; Androulakis, N.; Kalbakis, K.; Samonis, G.; Mavroudis, D. Second-line treatment with irinotecan plus cisplatin vs cisplatin of patients with advanced non-small-cell lung cancer pretreated with taxanes and gemcitabine: a multicenter randomised phase II study. Br. J. Cancer, 2005, 93(7), 763-769.
11. Androulakis, N.; Aravantinos, G.; Syrigos, K.; Polyzos, A.; Ziras, N.; Tselepatiotis, E.; Samonis, G.; Kentepozidis, N.; Giassas, S.; Vamvakas, L.; Georgoulias, V. Oxaliplatin as first-line treatment in inoperable biliary tract carcinoma: a multicenter phase II study. Oncology, 2006, 70(4), 280-284.
12. Kakolyris, S.; Ziras, N.; Vamvakas, L.; Varthalitis, J.; Papakotoulas, P.; Syrigos, K.; Vardakis, N.; Kalykaki, A.; Amarantidis, K.; Georgoulias, V. Gemcitabine plus oxaliplatin combination (GEMOX regimen) in pretreated patients with advanced non-small cell lung cancer (NSCLC): a multicenter phase II study. Lung Cancer, 2006, 54(3), 347-352.
13. Androulakis, N.; Syrigos, K.; Polyzos, A.; Aravantinos, G.; Stathopoulos, G.P.; Ziras, N.; Mallas, K.; Vamvakas, L.; Georgoulis, V. Oxaliplatin for pretreated patients with advanced or metastatic pancreatic cancer: a multicenter phase II study. Cancer Invest., 2005, 23(1), 9-12.
14. Souglakos, J.; Androulakis, N.; Syrigos, K.; Polyzos, A.; Ziras, N.; Athanasiadis, A.; Kakolyris, S.; Tsousis, S.; Kouroussis, C.; Vamvakas, L.; Kalykaki, A.; Samonis, G.; Mavroudis, D.; Georgoulias, V. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br. J. Cancer, 2006, 94(6), 798-805.
15. Zanotti, K.M.; Rybicki, L.A.; Kennedy, A.W.; Belinson, J.L.; Webster, K.D.; Kulp, B.; Peterson, G.; Markman, M. Carboplatin skin testing: a skin-testing protocol for predicting hypersensitivity to carboplatin chemotherapy. J. Clin. Oncol., 2001, 19(12), 3126-3129.
16. Georgoulias, V.; Ardavanis, A.; Tsiafaki, X.; Agelidou, A.; Mixalopoulou, P.; Anagnostopoulou, O.; Ziotopoulos, P.; Toubis, M.; Syrigos, K.; Samaras, N.; Polyzos, A.; Christou, A.; Kakolyris, S.; Kouroussis, C.; Androulakis, N.; Samonis, G.; Chatzidaki, D. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J. Clin. Oncol., 2005, 23(13), 2937-2945.
17. Ziras, N.; Potamianou, A.; Varthalitis, I.; Syrigos, K.; Tsousis, S.; Boukovinas, I.; Tselepatiotis, E.; Christofillakis, C.; Georgoulias, V. Multicenter phase II study of gemcitabine and oxaliplatin (GEMOX) as second-line chemotherapy in colorectal cancer patients pretreated with 5-fluorouracil plus irinotecan. Oncology, 2006, 70(2), 106-114.
18. Souglakos, J.; Syrigos, K.; Potamianou, A.; Polyzos, A.; Boukovinas, I.; Androulakis, N.; Kouroussis, C.; Vardakis, N.; Christophilakis, C.; Kotsakis, A.; Georgoulias, V. Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial. Ann. Oncol., 2004, 15(8), 1204-1209.
19. Kim, B.H.; Bradley, T.; Tai, J.; Budman, D.R. Hypersensitivity to oxaliplatin: an investigation of incidence and risk factors, and literature review. Oncology, 2009, 76(4), 231-238.
20. Lenz, H.J. Management and preparedness for infusion and hypersensitivity reactions. Oncologist, 2007, 12(5), 601-609.
21. Okada, N.; Ishibashi, K.; Kuwabara, K.; Ishiguro, T.; Hatano, S.; Hokama, N.; Tajima, Y.; Ishii, M.; Kubota, S.; Chika, N.; Miyazaki, T.; Ishida, H. [The prognosis of patients with an allergic reaction in the treatment of mFOLFOX6 therapy]. Gan To Kagaku Ryoho, 2009, 36(12), 1985-1987.
22. Hewitt, M.R.; Sun, W. Oxaliplatin-associated hypersensitivity reactions: clinical presentation and management. Clin. Colorectal Cancer, 2006, 6(2), 114-117.
23. Syrigou, E.; Syrigos, K.; Saif, M.W. Hypersensitivity reactions to oxaliplatin and other antineoplastic agents. Curr. Allergy Asthma Rep., 2008, 8(1), 56-62.
24. Saif, M.W.; Roy, S.; Ledbetter, L.; Madison, J.; Syrigos, K. Fever as the only manifestation of hypersensitivity reactions associated with oxaliplatin in a patient with colorectal cancer Oxaliplatininduced hypersensitivity reaction. World J. Gastroenterol., 2007, 13(39), 5277-5281.
25. Bautista, M.A.; Stevens, W.T.; Chen, C.S.; Curtis, B.R.; Aster, R.H.; Hsueh, C.T. Hypersensitivity reaction and acute immunemediated thrombocytopenia from oxaliplatin: two case reports and a review of the literature. J. Hematol. Oncol., 2010, 3,12.
26. Garufi, C.; Vaglio, S.; Brienza, S.; Conti, L.; D'Attino, R.M.; Girelli, G.; Terzoli, E. Immunohemolytic anemia following oxaliplatin administration. Ann. Oncol., 2000, 11(4), 497.
27. de Vries, R.S.; Mattijssen, E.J.; van Sorge, A.A. Serious delayed hypersensitivity reaction to oxaliplatin. Ann. Oncol., 2006, 17(11), 1723-1724.
28. Santini, D.; Tonini, G.; Salerno, A.; Vincenzi, B.; Patti, G.; Battistoni, F.; Dicuonzo, G.; Labianca, R. Idiosyncratic reaction after oxaliplatin infusion. Ann. Oncol., 2001, 12(1), 132-133.
29. Tonini, G.; Santini, D.; Vincenzi, B.; Borzomati, D.; Dicuonzo, G.; La, C.A.; Onori, N.; Coppola, R. Oxaliplatin may induce cytokinerelease syndrome in colorectal cancer patients. J. Biol. Regul. Homeost. Agents, 2002, 16(2), 105-109.
30. Ichikawa, Y.; Goto, A.; Hirokawa, S.; Kijima, M.; Ishikawa, T.; Chishima, T.; Suwa, H.; Yamamoto, H.; Yamagishi, S.; Osada, S.; Ota, M.; Fujii, S. Allergic reactions to oxaliplatin in a single institute in Japan. Jpn. J. Clin. Oncol., 2009, 39(9), 616-620.
31. Lee, C.; Gianos, M.; Klaustermeyer, W.B. Diagnosis and management of hypersensitivity reactions related to common cancer chemotherapy agents. Ann. Allergy Asthma Immunol., 2009, 102(3), 179-187.
32. Pietrantonio, F.; Di, B.M.; Buzzoni, R.; Bajetta, E. Acute immunemediated thrombocytopenia due to oxaliplatin administration: a case report. Tumori, 2010, 96(1), 154-156.
33. Vekris, A.; Meynard, D.; Haaz, M.C.; Bayssas, M.; Bonnet, J.; Robert, J. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research. Cancer Res., 2004, 64(1), 356-362.
34. Greene, D.P.; Ferriss, J.S.; Jazaeri, A.A. Cisplatin administration following carboplatin desensitization failure in primary peritoneal cancer: a brief report. Cancer Chemother. Pharmacol., 2010, 66(2), 265-267.
35. Sharma, R.; Sinha, R.; Menon, P.S.; Sirohi, D. Management protocol for anaphylaxis. J. Oral Maxillofac. Surg., 2010, 68(4), 855-862.
36. Gadducci, A.; Tana, R.; Teti, G.; Zanca, G.; Fanucchi, A.; Genazzani, A.R. Analysis of the pattern of hypersensitivity reactions in patients receiving carboplatin retreatment for recurrent ovarian cancer. Int. J. Gynecol. Cancer, 2008, 18(4), 615-620.
37. Gomez, R.; Harter, P.; Luck, H.J.; Traut, A.; Kommoss, S.; Kandel, M.; du, B.A. Carboplatin hypersensitivity: does introduction of skin test and desensitization reliably predict and avoid the problem? A prospective single-center study. Int. J. Gynecol. Cancer, 2009, 19(7), 1284-1287.
38. Dizon, D.S.; Sabbatini, P.J.; Aghajanian, C.; Hensley, M.L.; Spriggs, D.R. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy. Gynecol. Oncol., 2002, 84(3), 378-382.
39. Hoekstra, A.V.; Hurteau, J.A.; Kirschner, C.V.; Rodriguez, G.C. The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer. Gynecol. Oncol., 2009, 115(3), 377-381.
40. Castells, M.C.; Tennant, N.M.; Sloane, D.E.; Hsu, F.I.; Barrett, N.A.; Hong, D.I.; Laidlaw, T.M.; Legere, H.J.; Nallamshetty, S.N.; Palis, R.I.; Rao, J.J.; Berlin, S.T.; Campos, S.M.; Matulonis, U.A. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J. Allergy Clin. Immunol., 2008, 122(3), 574-580.
41. Limsuwan, T.; Castells, M.C. Outcomes and safety of rapid desensitization for chemotherapy hypersensitivity. Expert. Opin. Drug Saf, 2010, 9(1), 39-53.
42. Gkiozos, I.; Charpidou, A.; Syrigos, K. Developments in the treatment of non-small cell lung cancer. Anticancer Res., 2007, 27(4C), 2823-2827.
43. Nishio, S.; Koyanagi, T.; Miyabe, K.; Kuromatsu, H. [Successful desensitization protocol for patients with hypersensitivity reactions caused by carboplatin]. Gan To Kagaku Ryoho, 2010, 37(4), 731-733.
44. Montiel Herrera, J.M.; Gongora-Melendez, M.A.; Pineda-Maldonado, M.L.; Medina-Sanson, A.; Del Rio Chivardi, J.M.; Del Rio-Navarro, B.E.; Rosas-Vargas, M.A. Carboplatin Hypersensitivity and Desensitization in an Infant. Ther. Drug Monit., 2010 May 11 [Epub ahead of print].
45. Abe, A.; Ikawa, H.; Ikawa, S. Desensitization treatment with cisplatin after carboplatin hypersensitivity reaction in gynecologic cancer. J. Med. Invest., 2010, 57(1-2), 163-167.
46. Syrigou, E.; Makrilia, N.; Vassias, A.; Nikolaidis, I.; Xyla, V.; Manolopoulos, L.; Syrigos, K. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful? Anticancer Drugs, 2010, 21(3), 333-338.
47. Markman, M.; Moon, J.; Wilczynski, S.; Lopez, A.M.; Rowland, K.M., Jr.; Michelin, D.P.; Lanzotti, V.J.; Anderson, G.L.; Alberts, D.S. Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial. Gynecol. Oncol., 2010, 116(3), 323-325.
48. Thomas, R.R.; Quinn, M.G.; Schuler, B.; Grem, J.L. Hypersensitivity and idiosyncratic reactions to oxaliplatin. Cancer, 2003, 97(9), 2301-2307.
49. Alliot, C.; Messouak, D.; Beets, C.; Rapin, J.P. Severe anaphylactic reaction to oxaliplatin. Clin. Oncol. (R. Coll. Radiol.), 2001, 13(3), 236.
50. Giacchetti, S.; Perpoint, B.; Zidani, R.; Le, B.N.; Faggiuolo, R.; Focan, C.; Chollet, P.; Llory, J.F.; Letourneau, Y.; Coudert, B.; Bertheaut-Cvitkovic, F.; Larregain-Fournier, D.; Le, R.A.; Walter, S.; Adam, R.; Misset, J.L.; Levi, F. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J. Clin. Oncol., 2000, 18(1), 136-147.
51. Shibata, Y.; Ariyama, H.; Baba, E.; Takii, Y.; Esaki, T.; Mitsugi, K.; Tsuchiya, T.; Kusaba, H.; Akashi, K.; Nakano, S. Oxaliplatininduced allergic reaction in patients with colorectal cancer in Japan. Int. J. Clin. Oncol., 2009, 14(5), 397-401.
52. Syrigou, E.I.; Karapanagiotou, E.M.; Alamara, C.V.; Boura, P.G.; Saif, M.W.; Syrigos, K.N. Hypersensitivity reactions to oxaliplatin: a retrospective study and the development of a desensitization protocol. Clin. Colorectal Cancer, 2009, 8(2), 106-109.
53. Rodriguez-Antona, C. Pharmacogenomics of paclitaxel. Pharmacogenomics, 2010, 11(5), 621-623.
54. Baker, J.; Ajani, J.; Scotte, F.; Winther, D.; Martin, M.; Aapro, M.S.; von, M.G. Docetaxel-related side effects and their management. Eur. J. Oncol. Nurs., 2009, 13(1), 49-59.
55. Quock, J.; Dea, G.; Tanaka, M.; Gandara, D.; Lara, P.; Lau, D. Premedication strategy for weekly paclitaxel. Cancer Invest., 2002, 20(5-6), 666-672.
56. Kosmidis, P.A.; Kalofonos, H.P.; Christodoulou, C.; Syrigos, K.; Makatsoris, T.; Skarlos, D.; Bakogiannis, C.; Nicolaides, C.; Bafaloukos, D.; Bamias, A.; Samantas, E.; Xiros, N.; Boukovinas, I.; Fountzilas, G.; Dimopoulos, M.A. Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced nonsmall- cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. Ann. Oncol., 2008, 19(1), 115-122.
57. Alsamarai, S.; Charpidou, A.G.; Matthay, R.A.; Confeld, D.; Syrigos, K.N.; Saif, M.W. Pneumonitis related to docetaxel: case report and review of the literature. In Vivo, 2009, 23(4), 635-637.
58. Syrigos, K.N.; Michalaki, B.; Alevyzaki, F.; Machairas, A.; Mandrekas, D.; Kindilidis, K.; Karatzas, G. A phase-II study of liposomal doxorubicin and docetaxel in patients with advanced pancreatic cancer. Anticancer Res., 2002, 22(6B), 3583-3588.
59. Polyzos, A.; Tsavaris, N.; Kosmas, C.; Gogas, H.; Vadiaka, M.; Markopoulos, C.; Giannopoulos, A.; Kalahanis, N.; Stamatiadis, D.; Kouraklis, G.; Karatzas, G.; Liapis, C.; Syrigos, K. Docetaxel and epirubicin supported by granulocyte colony-stimulating factor first-line in advanced breast cancer. Anticancer Res., 2003, 23(3C), 2917-2923.
60. Karapanagiotou, E.M.; Charpidou, A.; Tzannou, I.; Dilana, K.; Kotteas, E.; Tourkantonis, I.; Kosmas, E.; Provata, A.; Syrigos, K. A phase II study of sequential docetaxel and gemcitabine followed by docetaxel and carboplatin as first-line therapy for non-small cell lung cancer. Med. Oncol., 2008, 25(3), 303-308.
61. Syrigos, K.N.; Karapanagiotou, E.; Charpidou, A.; Dilana, K.; Dannos, I.; Dionellis, G.; Rigopoulou, A.; Georgatou, N.; Roussos, C. Biweekly administration of docetaxel and gemcitabine for elderly patients with advanced non-small cell lung cancer: a phase II study. J. Chemother., 2007, 19(4), 438-443.
62. Syrigos, K.N.; Konstantinou, M.; Sepsas, E.; Papamichales, G.; Loullias, A.; Belenis, I.; Skottis, I.; Charpidou, A.; Roussos, C. Biweekly administration of docetaxel and gemcitabine as adjuvant therapy for stage II and IIIA non-small cell lung cancer: a phase II study. Anticancer Res., 2007, 27(4C), 2887-2892.
63. Brown, S.G. Antihistamines for anaphylaxis? Primary outcome measures. Br. Med. J., 2009, 339(b3368).
64. Agelaki, S.; Veslemes, M.; Syrigos, K.; Palamidas, F.; Polyzos, A.; Papakotoulas, P.; Kentepozidis, N.; Milaki, G.; Tzanakis, N.; Kouroussis, C.; Vamvakas, L.; Georgoulias, V. A multicenter phase II study of the combination of gemcitabine and docetaxel in previously treated patients with small cell lung cancer. Lung Cancer, 2004, 43(3), 329-333.
65. Georgoulias, V.; Ardavanis, A.; Agelidou, A.; Agelidou, M.; Chandrinos, V.; Tsaroucha, E.; Toumbis, M.; Kouroussis, C.; Syrigos, K.; Polyzos, A.; Samaras, N.; Papakotoulas, P.; Christofilakis, C.; Ziras, N.; Alegakis, A. Docetaxel versus docetaxel plus cisplatin as front-line treatment of patients with advanced non-small-cell lung cancer: a randomized, multicenter phase III trial. J. Clin. Oncol., 2004, 22(13), 2602-2609.
66. Syrigos, K.N.; Dannos, I.; Dionellis, G.; Bofos, I.; Alamara, C.; Dimakou, E.; Stratakos, G.; Papiris, S. Bi-weekly administration of docetaxel and gemcitabine as first-line therapy for non-small cell lung cancer: a phase II study. Anticancer Res., 2005, 25(5), 3489-3493.
67. Kloover, J.S.; den Bakker, M.A.; Gelderblom, H.; van Meerbeeck, J.P. Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens. Br. J. Cancer, 2004, 90(2), 304-305.
68. Ralli, M.; Tourkantonis, I.; Makrilia, N.; Gkini, E.; Kotteas, E.; Gkiozos, I.; Katirtzoglou, N.; Syrigos, K. Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res., 2009, 29(8), 3441-3444.
69. Tourkantonis, I.; Makrilia, N.; Ralli, M.; Alamara, C.; Nikolaidis, I.; Tsimpoukis, S.; Charpidou, A.; Kotanidou, A.; Syrigos, K. Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleural mesothelioma: a single institution study. Am. J. Clin. Oncol., 2010 May 3 [Epub ahead of print].
70. Mavroudis, D.; Papakotoulas, P.; Ardavanis, A.; Syrigos, K.; Kakolyris, S.; Ziras, N.; Kouroussis, C.; Malamos, N.; Polyzos, A.; Christophyllakis, C.; Kentepozidis, N.; Georgoulias, V. Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann. Oncol., 2010, 21(1), 48-54.
71. Markman, M.; Kennedy, A.; Webster, K.; Kulp, B.; Peterson, G.; Belinson, J. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center. J. Clin. Oncol., 2000, 18(1), 102-105.
72. Pinder, M.C.; Ibrahim, N.K. Nanoparticle albumin-bound paclitaxel for treatment of metastatic breast cancer. Drugs Today (Barc.), 2006, 42(9), 599-604.
73. Gradishar, W.J.; Tjulandin, S.; Davidson, N.; Shaw, H.; Desai, N.; Bhar, P.; Hawkins, M.; O'Shaughnessy, J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol., 2005, 23(31), 7794-7803.
74. Ardavanis, A.; Tryfonopoulos, D.; Yiotis, I.; Gerasimidis, G.; Baziotis, N.; Rigatos, G. Non-allergic nature of docetaxel-induced acute hypersensitivity reactions. Anticancer Drugs, 2004, 15(6), 581-585.
75. Moisidis, C.; Mobus, V. Erythema multiforme major following docetaxel. Arch. Gynecol. Obstet., 2005, 271(3), 267-269.
76. Kwon, J.S.; Elit, L.; Finn, M.; Hirte, H.; Mazurka, J.; Moens, F.; Trim, K. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel. Gynecol. Oncol., 2002, 84(3), 420-425.
77. Komatsubara, K.; Miyoshi, K.; Kogure, Y.; Matsuhisa, T.; Eguchi, H. [Administration of premedication with fexofenadine for paclitaxel-induced hypersensitive reactions in breast cancer patients complicated with closed-angle glaucoma]. Gan To Kagaku Ryoho, 2010, 37(1), 107-110.
78. Markman, M. Managing taxane toxicities. Support. Care Cancer, 2003, 11(3), 144-147.
79. Feldweg, A.M.; Lee, C.W.; Matulonis, U.A.; Castells, M. Rapid desensitization for hypersensitivity reactions to paclitaxel and docetaxel: a new standard protocol used in 77 successful treatments. Gynecol. Oncol., 2005, 96(3), 824-829.
80. Moon, C.; Verschraegen, C.F.; Bevers, M.; Freedman, R.; Kudelka, A.P.; Kavanagh, J.J. Use of docetaxel (Taxotere) in patients with paclitaxel (Taxol) hypersensitivity. Anticancer Drugs, 2000, 11(7), 565-568.
81. Syrigou, E.; Makrilia, N.; Koti, I.; Saif, M.W.; Syrigos, K.N. Hypersensitivity reactions to antineoplastic agents: an overview. Anticancer Drugs, 2009, 20(1), 1-6.
82. Dizon, D.S.; Schwartz, J.; Rojan, A.; Miller, J.; Pires, L.; Disilvestro, P.; Gordinier, M.E.; Moore, R.; Granai, C.O.; Legare, R.D. Cross-sensitivity between paclitaxel and docetaxel in a women's cancers program. Gynecol. Oncol., 2006, 100(1), 149-151.
83. Green, M.R.; Manikhas, G.M.; Orlov, S.; Afanasyev, B.; Makhson, A.M.; Bhar, P.; Hawkins, M.J. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann. Oncol., 2006, 17(8), 1263-1268.
84. Fader, A.N.; Rose, P.G. Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. Int. J. Gynecol. Cancer, 2009, 19(7), 1281-1283.
85. Holcenberg, J. Optimal asparaginase therapy. J. Pediatr. Hematol. Oncol., 2004, 26(5), 273-274.
86. Pectasides, D.; Samantas, E.; Fountzilas, G.; Briasoulis, E.; Kosmidis, P.; Skarlos, D.; Dimopoulos, M.A.; Kalofonos, H.P.; Economopoulos, T.; Syrigos, K. Combination chemotherapy with cisplatin, etoposide and irinotecan in patients with extensive smallcell lung cancer: A phase II study of the Hellenic Co-operative Oncology Group. Lung Cancer, 2007, 58(3), 355-361.
87. Ignatiadis, M.; Mavroudis, D.; Veslemes, M.; Boukovinas, J.; Syrigos, K.; Agelidou, M.; Agelidou, A.; Gerogianni, A.; Pavlakou, G.; Tselepatiotis, E.; Nikolakopoulos, J.; Georgoulias, V. Sequential versus alternating administration of cisplatin/etoposide and topotecan as first-line treatment in extensive-stage small-cell lung cancer: preliminary results of a Phase III Trial of the Hellenic Oncology Research Group. Clin. Lung Cancer, 2005, 7(3), 183-189.
88. Charpidou, A.; Tsagouli, S.; Tsimpoukis, S.; Vassias, A.; Makrilia, N.; Stratakos, G.; Gkiozos, I.; Syrigos, K. Triplet combination of carboplatin, irinotecan, and etoposide in the first-line treatment of extensive small-cell lung cancer: a single-institution phase II study. Anticancer Drugs, 2010, 21(6), 651-655.
89. Collier, K.; Schink, C.; Young, A.M.; How, K.; Seckl, M.; Savage, P. Successful treatment with etoposide phosphate in patients with previous etoposide hypersensitivity. J. Oncol. Pharm. Pract., 2008, 14(1), 51-55.
90. Siderov, J.; Prasad, P.; De, B.R.; Desai, J. Safe administration of etoposide phosphate after hypersensitivity reaction to intravenous etoposide. Br. J. Cancer, 2002, 86(1), 12-13.
91. Chanan-Khan, A.; Szebeni, J.; Savay, S.; Liebes, L.; Rafique, N.M.; Alving, C.R.; Muggia, F.M. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann. Oncol., 2003, 14(9), 1430-1437.
92. Chan, A.; Shih, V.; Tham, C.K. Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures. J. Oncol. Pharm. Pract., 2007, 13(2), 105-107.